Genomics to Headline Anti-Cancer Drug Discovery & Development Conference in Princeton, NJ, June 11 & 12

Apr 13, 2001, 01:00 ET from Strategic Research Institute

    PRINCETON, N.J., April 13 /PRNewswire/ -- Late-breaking advances in
 anti-cancer research in genomics, therapeutic antibodies, angiogenesis, and
 new molecular targets at the pre-clinical and clinical stages will be the
 focus of the "2nd International Anti-Cancer Drug Discovery & Development
 Summit" taking place in Princeton, NJ on June 11-12, 2001, announces Strategic
 Research Institute.
     Presentations on applications of genomics in cancer will be given by
 Celera Genomics, Hoffman-La Roche, Schering Plough, and Eos Biotechnology, all
 of whom are using genomics for drug discovery and development against a
 variety of human cancers.
     The meeting, divided into five discrete sections, 1) new molecular
 targets, 2) therapeutic antibodies, 3) applied genomics in cancer,
 4) angiogenic advances, and 5) novel therapeutics, will feature prominent
 pharmaceutical, biotechnology, and academic scientists revealing their newest
 findings.
     Also presenting papers on behalf of the industry will be Novartis, Merck,
 Amgen, Hoffmann-La Roche, Bristol-Myers Squibb, Eli Lilly, Schering-Plough,
 Wyeth Ayerst, Millennium Pharmaceuticals, Celera Genomics, EntreMed, ILEX
 Oncology, Cytokinetics , Eos Biotechnology, ImClone Systems, Medarex, Biomira,
 and Ceretek, while Columbia University and Georgetown University will
 represent the academic community.
 
     Other highlights of the program include:
 
     -- Selective Estrogen Receptor Modulators (SERMs) by ELI LILLY
 
     -- Clinical Development of Therapeutic "Vaccines" Incorporating Synthetic
        Mimics of MUC1 Cancer Antigens by BIOMIRA
 
     -- Edg Receptors: New Tools & Targets for Anticancer Drug Discovery by
        CERETEK
 
     To receive the full agenda and/or register for the conference, please
 contact Jon Liong of Strategic Research Institute at jliong@srinstitute.com or
 212-967-0095, ext. 243 (please include name, corporate affiliation,
 mailing address, and fax number).
     To register as an exhibitor or to sponsor a function, please contact Mark
 Alexay at malexay@srinstitute.com.
 
 

SOURCE Strategic Research Institute
    PRINCETON, N.J., April 13 /PRNewswire/ -- Late-breaking advances in
 anti-cancer research in genomics, therapeutic antibodies, angiogenesis, and
 new molecular targets at the pre-clinical and clinical stages will be the
 focus of the "2nd International Anti-Cancer Drug Discovery & Development
 Summit" taking place in Princeton, NJ on June 11-12, 2001, announces Strategic
 Research Institute.
     Presentations on applications of genomics in cancer will be given by
 Celera Genomics, Hoffman-La Roche, Schering Plough, and Eos Biotechnology, all
 of whom are using genomics for drug discovery and development against a
 variety of human cancers.
     The meeting, divided into five discrete sections, 1) new molecular
 targets, 2) therapeutic antibodies, 3) applied genomics in cancer,
 4) angiogenic advances, and 5) novel therapeutics, will feature prominent
 pharmaceutical, biotechnology, and academic scientists revealing their newest
 findings.
     Also presenting papers on behalf of the industry will be Novartis, Merck,
 Amgen, Hoffmann-La Roche, Bristol-Myers Squibb, Eli Lilly, Schering-Plough,
 Wyeth Ayerst, Millennium Pharmaceuticals, Celera Genomics, EntreMed, ILEX
 Oncology, Cytokinetics , Eos Biotechnology, ImClone Systems, Medarex, Biomira,
 and Ceretek, while Columbia University and Georgetown University will
 represent the academic community.
 
     Other highlights of the program include:
 
     -- Selective Estrogen Receptor Modulators (SERMs) by ELI LILLY
 
     -- Clinical Development of Therapeutic "Vaccines" Incorporating Synthetic
        Mimics of MUC1 Cancer Antigens by BIOMIRA
 
     -- Edg Receptors: New Tools & Targets for Anticancer Drug Discovery by
        CERETEK
 
     To receive the full agenda and/or register for the conference, please
 contact Jon Liong of Strategic Research Institute at jliong@srinstitute.com or
 212-967-0095, ext. 243 (please include name, corporate affiliation,
 mailing address, and fax number).
     To register as an exhibitor or to sponsor a function, please contact Mark
 Alexay at malexay@srinstitute.com.
 
 SOURCE  Strategic Research Institute